Logo

DYCQU

DT Cloud Acquisition Corporation Unit

DYCQU

DT Cloud Acquisition Corporation Unit • NASDAQ
$12.51 ▲ 0.00% (+0.00)
Market Cap $36.56 M
52w High $14.00
52w Low $10.52
Dividend Yield 0%
P/E 0
Volume 20
Outstanding Shares 2.92M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $0 ▼ $-242.147K ▼ 0% $-0.09 ▼ $-331.511K ▼
Q2-2025 $0 $269.124K ▼ $234.657K ▼ 0% $0.035 ▼ $-269.124K ▲
Q1-2025 $0 $288.262K ▲ $452.085K ▼ 0% $0.051 ▼ $-288K ▼
Q4-2024 $0 $195.829K ▲ $632.803K ▼ 0% $0.071 ▼ $-196K ▼
Q3-2024 $0 $157.61K $760.262K 0% $0.085 $-158K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.598M ▲ $1.621M ▼ $3.282M ▲ $-3.259M ▼
Q2-2025 $0 $9.103M ▼ $3.016M ▲ $6.088M ▼
Q1-2025 $0 ▼ $53.691M ▼ $2.569M ▲ $51.122M ▼
Q4-2024 $152.021K ▼ $72.514M ▲ $2.023M ▲ $70.491M ▲
Q3-2024 $167.526K $71.722M $1.864M $69.858M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-242.147K ▼ $-49.35K ▲ $7.549M ▼ $-7.5M ▲ $0 $-49.35K ▲
Q2-2025 $234.657K ▼ $-344.834K ▼ $45.068M ▲ $-44.723M ▼ $0 ▲ $-344.834K ▼
Q1-2025 $452.085K ▼ $-253.559K ▼ $19.463M ▲ $-19.362M ▼ $-152.02K ▼ $-253.559K ▼
Q4-2024 $632.803K ▼ $-15.505K ▲ $1.128M ▲ $-1.134M ▼ $-15.505K ▲ $-15.505K ▲
Q3-2024 $760.262K $-161.037K $-1.5M $1.507M $-146.876K $-146.876K

Five-Year Company Overview

Income Statement

Income Statement DYCQU’s income statement reflects what it is: a SPAC shell, not an operating business. There is essentially no revenue, no gross profit, and no traditional operating income. The swing in per‑share results in the most recent year likely comes from SPAC‑specific accounting items (such as changes in warrant values or trust‑related adjustments), not from selling products or services. In practical terms, there is no underlying business performance to analyze yet, only deal and structure effects.

Balance Sheet

Balance Sheet The balance sheet is very light and simple, with a small layer of equity and essentially no reported debt, which is typical for a SPAC at this stage. Most of the economic value for SPACs sits in the IPO trust account rather than in operating assets, which is not fully visible in the simplified numbers provided. The structure is designed to be low‑leverage and temporary: capital is held and protected until a transaction is completed or the vehicle is wound down. The key risk is not balance sheet strain in the usual sense, but whether the SPAC can complete a viable deal before deadlines or forced liquidation, especially now that it faces delisting pressure.

Cash Flow

Cash Flow Cash flows are minimal and largely administrative. There is no real operating cash inflow, since the company has no business activities, customers, or products. Cash use mainly relates to SPAC running costs, legal and advisory fees, and efforts tied to the attempted merger. Free cash flow is not a meaningful metric here, because the structure is designed to hold IPO proceeds in trust rather than to generate ongoing cash earnings. The main cash flow question is what ultimately happens to the trust funds under different outcomes: successful merger, failed merger with redemption, or liquidation.

Competitive Edge

Competitive Edge As a SPAC, DYCQU has no operating franchise, customer base, or traditional competitive moat. Its only “product” is the opportunity to merge with a private company. The environment has become crowded and much tougher, with many SPACs chasing a limited pool of attractive targets while regulators and exchanges have tightened standards. The Nasdaq notice for non‑compliance and the risk of delisting weaken its standing further: targets generally prefer a stable listing partner. In practice, DYCQU’s competitive position is now fragile, heavily constrained by market sentiment toward SPACs and by its own listing and deal uncertainties.

Innovation and R&D

Innovation and R&D DYCQU itself does not conduct research or own technology; it is purely a financial vehicle. The innovation story sat with its intended target, Maius Pharmaceutical, which focuses on novel small‑molecule and peptide drugs for cancer, autoimmune disease, and infections, using an integrated platform for drug discovery and delivery. That platform could have offered a differentiated edge in developing targeted therapies. However, with the merger vote canceled and the company facing delisting, these R&D strengths are not actually owned or controlled by DYCQU. At this stage, there is no clear line of sight to any innovation engine within the SPAC, only a stalled plan to access one through Maius.

Summary

DYCQU is an early‑stage SPAC with no operating business, no revenue, and minimal traditional financial history. Its structure is clean and simple, with low leverage and capital held for a potential deal, but its value has always depended entirely on completing a merger. The attempted combination with Maius Pharmaceutical offered a compelling R&D story in biopharma, yet recent events—Nasdaq’s non‑compliance notice, delisting risk, and the cancellation of the shareholder meeting—cast serious doubt on that path. From here, the key factors are not margins or growth rates, but event‑driven outcomes: whether the SPAC can regain compliance, secure a new or revised transaction, or ultimately unwind and return funds. The overall picture is one of high uncertainty, where structural and regulatory issues dominate any discussion of long‑term business prospects.